Abstract:The periostin protein, encoded by the POSTN gene, is a component of the extracellular matrix, which is expressed by fibroblasts and has been observed in a variety of human malignancies. The present study aimed to detect the expression of periostin in the tissues of non-small cell lung cancer (NSCLC) patients and benign lung tumors, and to correlate the results with the clinicopathological data of the subjects, in order to evaluate periostin as a potential prognostic marker. In total, 49 NSCLC patients and 6 benign lung tumors were included in this study. The protein level of periostin was detected in paired normal/paratumor/cancer tissues by a western blot analysis and the mRNA level in paired normal/cancer tissues was detected by quantitative polymerase chain reaction (qPCR). The results were then correlated with established biological and prognostic factors. Immunohistochemistry was used to confirm the location of periostin in the NSCLC tissues. Uni- and multivariate analyses were performed using Cox's proportional hazards regression model. The protein level of periostin was elevated in the cancer tissue of the NSCLC patients compared with the normal (P=0.017) and paratumor (P=0.000) tissues. The expression level in the male patients was much higher than in the female patients at the protein (P=0.001) and mRNA (P=0.010) levels. The mRNA level in the non-adenocarcinoma (non-ADC) patients was much higher than in the adenocarcinoma (ADC) patients (P=0.029). Periostin was demonstrated higher expression at the protein level in the pseudotumors and tuberculosis patients than in the adjacent (P=0.016) and surrounding tissues (P=0.001). Immunostaining indicated that high levels of periostin were present in the mesenchymal areas, but not in the cancer cells themselves. The patients with tumors exhibiting high-level periostin expression showed a significantly shorter survival time (P=0.036, log-rank test). The 3-year survival rate was 81.5% for patients with low-level periostin expression (periostin-L; n=27) and 45.4% for patients with high-level periostin expression (periostin-H; n=22). Similarly, pathological node (pN) status was a significant prognostic marker in the univariate Cox survival analysis. Notably, periostin-H expression was also identified as an independent prognostic factor by the multivariate analysis (P=0.011). These results showed that the overexpression of periostin predicts a poor prognosis, therefore it may be regarded as a novel molecule in the progression and development of NSCLC. The results provide an additional target for the adjuvant treatment of NSCLC.

Identification of Serum Periostin as a Potential Diagnostic and Prognostic Marker for Colorectal Cancer.

Periostin expression in intra-tumoral stromal cells is prognostic and predictive for colorectal carcinoma via creating a cancer-supportive niche.

Periostin Expression and Its Prognostic Value for Colorectal Cancer.

Circulating Levels Of Periostin May Help Identify Patients With More Aggressive Colorectal Cancer

Periostin As A Promising Target of Therapeutical Intervention for Colorectal Cancer

High Preoparative Levels of Serum Periostin Are Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma after Hepatectomy.

Prognostic Value of Periostin in Multiple Solid Cancers: A Systematic Review with Meta‐analysis

Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer

Prognostic Significance of Periostin in Colorectal Cancer.

Serum periostin is a potential biomarker for non-alcoholic fatty liver disease: a case–control study

Diagnostic Potential Of Serum Exosomal Colorectal Neoplasia Differentially Expressed Long Non-Coding Rna (Crnde-P) And Microrna-217 Expression In Colorectal Carcinoma

Cancer Stem Cell-Related Gene Periostin: A Novel Prognostic Marker For Breast Cancer

Soluble POSTN is a novel biomarker complementing CA153 and CEA for breast cancer diagnosis and metastasis prediction

Overexpression of Periostin Predicts Poor Prognosis in Non-Small Cell Lung Cancer.

Research of Periostin in Cancer

Predictive and Prognostic Value of Serum Periostin in Advanced Non–small Cell Lung Cancer Patients Receiving Chemotherapy

miRNAs-mediated overexpression of Periostin is correlated with poor prognosis and immune infiltration in lung squamous cell carcinoma

Effects of Periostin on Hepatocellular Carcinoma Cells Invasion, Metastasis and Prognosis

Diagnostic value of periostin in lung cancer‐related malignant pleural effusion

Prognostic Role of Serum AZGP1, PEDF and PRDX2 in Colorectal Cancer Patients

Application of Periostin in diagnosis of colorectal cancer